Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.ZTE and ZTE Xinyun jointly released a digital intelligence financial solution. Recently, ZTE and ZTE Xinyun Cloud Service Co., Ltd. (referred to as "ZTE Xinyun") jointly released a digital intelligence financial solution based on digital nebula. The solution provides one-stop financial cloud application, fully supports financial functions and financial processes, solves breakpoints and pain points in the interaction between industry and finance, breaks the "data island" between systems, realizes the intelligent and efficient collection of business data and financial processing, and empowers the intelligent transformation of enterprise financial data.
New World Development sold Artisan Lab in Kowloon, Hong Kong for HK$ 620 million. Sing Tao Daily quoted an unnamed insider as saying that New World Development sold Artisan Lab in San Po Kong, Kowloon for HK$ 620 million. This 22-storey building was completed in 2022, with a floor area of about 120,000 square feet.The commander of Syrian democratic forces said that under the mediation of the US, Syrian rebels and Syrian democratic forces reached a ceasefire agreement in the northern city of Mambiji.Analyst: There may be a RRR cut of 50 basis points to 100 basis points next year. Tan Yiming, chief fixed income analyst of Minsheng Securities, said that there may be a RRR cut of 50 basis points to 100 basis points next year, considering the supply pressure of government bonds, the restoration of credit supply and the provision of long-term stable low-cost funds for financial institutions.
Australia's S&P/ASX200 index opened down 12.60 points, or 0.15%, at 8380.4 points on Wednesday, December 11th.Monetary policy has turned to "moderate easing", and experts say that it is expected to make greater efforts to lower the RRR and cut interest rates. The the Political Bureau of the Communist Party of China (CPC) Central Committee meeting held on December 9 changed the orientation of monetary policy from "steady" to "moderate easing" next year. Experts said that under the orientation of "moderate easing", the monetary policy space was further opened. In terms of total amount, it is more reasonable and sufficient to maintain liquidity; In terms of price, appropriately reducing the financing cost will better reflect the effectiveness of monetary policy. Next year, even greater RRR cuts and interest rate cuts can be expected. In addition to lowering the RRR and cutting interest rates, experts said that structural monetary policy tools, buying government bonds, open market buyout reverse repurchase and other operations are expected to continue to expand the scale, increase the frequency of use, and continuously enhance the effectiveness and pertinence of monetary policy. (CSI)Goldman Sachs: I don't agree that gold can't reach $3,000 under a strong dollar. Goldman Sachs said that we don't agree with the view that the price of gold can't rise to $3,000 per ounce by the end of 2025 when the dollar remains strong for a long time. We predict that gold will reach $3,000 per ounce by the end of 2025, and the reduction of interest rate cuts by the Federal Reserve (rather than the strengthening of the US dollar) is the downside risk of this prediction.